Printer Friendly

Keryx Biopharmaceuticals Inc (New York) said a mid-stage trial showed its colon cancer drug improved overall survival in heavily pre-treated patients with advanced metastatic colon cancer, as compared with a placebo.

Keryx Biopharmaceuticals Inc (New York) said a mid-stage trial showed its colon cancer drug improved overall survival in heavily pre-treated patients with advanced metastatic colon cancer, as compared with a placebo. The study enrolled a total of 38 patients, who were either given the drug KRX-0401, or perifosine, in combination with a chemotherapy drug capecitabine, or just capecitabine in combination with a placebo drug. Patients receiving KRX-0401 showed a greater than 60% improvement in overall survival and also demonstrated statistically significant advantage for time to progression, the company said. However, the patients on the drug showed a higher incidence of adverse events like anemia and hand-foot syndrome as compared with those on the placebo.

"We are eager to finalize the design of a Phase 3 protocol in metastatic colorectal cancer within the next 3 months, in consultation with the FDA, and to commence the Phase 3 study as soon as practicable thereafter," Chief Executive Ron Bentsur said. Perifosine is currently being tested in another late-stage trial for the treatment of relapsed/refractory multiple myeloma. Shares of the company closed the week off 13 cents at $2.61.
COPYRIGHT 2010 MedContent Media, Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2010 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Title Annotation:RESEARCH & TECHNOLOGY
Publication:MondayMorning
Article Type:Brief article
Date:Feb 1, 2010
Words:187
Previous Article:Burning sections of the heart works far better than drugs at treating patients with an irregular heartbeat condition called atrial fibrillation, a...
Next Article:Starting heparin in the emergency department (ED) rather than after admission may improve the survival of patients with acute pulmonary embolism...
Topics:

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters